Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 4Plasma cell 4Genitourinary 4Sarcoma 3Thoracic 2Lymphoid 2Other hematologic neoplasm 1Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Neoplasms 1Lymphoma 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × perifosine × Lymphoid × Clear all
NCT00398710 2018-03-15

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

AEterna Zentaris

Phase 2 Completed
37 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT00389077 2018-03-07

Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas

AEterna Zentaris

Phase 2 Completed
558 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡